SCHEMBL19732549

SCHEMBL19732549

Oc1cnc(C2CCCCCC2)c(-c2ccccccccc2)n1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
ADORA1 P30542 4/20 0.40
ADORA3 P0DMS8 3/20 0.40
ADORA2A P29274 2/20 0.40
POLB P06746 1/20 0.40
CASP3 P42574 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
NPY5R Q15761 1/20 0.39
CNR2 P34972 1/20 0.38
SSTR3 P32745 1/20 0.37
ATR Q13535 1/20 0.37
RAF1 P04049 1/20 0.37
PDE5A O76074 1/20 0.37
MAPT P10636 1/20 0.37
PDE10A Q9Y233 2/20 0.36
LCK P06239 1/20 0.36
NTRK1 P04629 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21013748 0.77 L3MBTL1 (0.35) TDP1L3MBTL1ATRLCK
SCHEMBL19333209 0.77 L3MBTL1 (0.35) TDP1L3MBTL1ATRLCK
SCHEMBL28079387 0.74 L3MBTL1 (0.58) TDP1L3MBTL1ADORA1ADORA3ADORA2A
SCHEMBL30478423 0.73 CKS1B (0.53) TDP1L3MBTL1ADORA1ADORA2AMAPT
SCHEMBL2036410 0.73 CKS1B (0.53) TDP1L3MBTL1ADORA1ADORA2AMAPT
SCHEMBL21013746 0.72 L3MBTL1 (0.33) TDP1L3MBTL1CNR2ATRLCK
SCHEMBL19333210 0.72 L3MBTL1 (0.33) TDP1L3MBTL1CNR2ATRLCK
SCHEMBL31364011 0.70 TDP1 (0.53) TDP1L3MBTL1ADORA1ADORA3ADORA2A
SCHEMBL7567737 0.68 CKS1B (0.43) L3MBTL1ADORA1ADORA2AMAPT
SCHEMBL28283878 0.67 ADORA2A (0.48) TDP1L3MBTL1ADORA1ADORA2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170362245-A1 TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES AS LSD1 INHIBITORS INCYTE CORPORATION 2017-12-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170362245-A1 TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES AS LSD1 INHIBITORS KDM1B, KDM5A, KDM1A TDP1 195/4885L3MBTL1 418/4885ADORA1 2860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.